6-Iodo-4-Hydroxyquinazoline CAS 16064-08-7 Purity >98.5% (HPLC) Factory
Chemical Name | 6-Iodo-4-Hydroxyquinazoline |
Synonyms | 6-Iodoquinazolin-4-one; 6-Iodo-4-Quinazolinone; 6-Iodoquinazolin-4(3H)-one; 6-Iodo-4(1H)-Quinazolinone; 6-Iodo-4-Quinazolinol |
CAS Number | 16064-08-7 |
Stock Status | In Stock, Production Scale Up to Tons |
Molecular Formula | C8H5IN2O |
Molecular Weight | 272.04 |
Melting Point | 271℃ (lit.) |
Density | 2.11±0.10 g/cm3 |
COA & MSDS | Available |
Origin | Shanghai, China |
Brand | Ruifu Chemical |
Item | Specifications | Specifications |
Appearance | Pale Yellow to Brown Crystal | Complies |
Identification | H-NMR, MS | Complies |
Loss on Drying | <1.00% | 0.45% |
Residue on Ignition | <0.10% | <0.10% |
Purity / Analysis Method | >98.5% (HPLC) | 98.79% (HPLC) |
1 H NMR Spectrum | Consistent With Structure | Complies |
Test Standard | Enterprise Standard | |
Usage | Intermediate of API (CAS: 388082-78-8) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Risk Codes
36 - Irritating to the eyes
Safety Description
26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
6-Iodo-4-Hydroxyquinazoline (CAS: 16064-08-7) is an intermediate in the synthesis of API (CAS: 388082-78-8). (CAS: 388082-78-8) is available in 250-mg tablets for oral administrationand is used in combination with Cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes.